Me Too Drugs: R&D Innovations or Imitations?Activity by Tanya Fogg | added on Mar 17, 2011 | United States
Sponsor(s): ACS Webinars
A “me too” drug is similar in chemical structure or has the same mechanism of action as the protype. According to the 2004 FDA report, only about one-third of the drug license application approvals over the preceding eight years were considered as ‘new’.
What are the merits of these me too drugs? Is the pharmaceuticals industry providing enhanced therapeutic options or creating wasteful resources? Bring your ideas and join us to get your dose of me too analysis with speaker, Joe DiMasi, of Tufts University! Join us LIVE to have YOUR questions answered!
What You Will Learn
• Trends in the Speed of Competitive Entry in Drug Classes
• Knock-offs or Win, Place, and Show: Are Me-Toos Copycats or Losers in a Development Race?
• First-in-Class versus Me-Toos: Who Develops and Who Patents First?
• Are First-in-Class Drugs Always Best-in-Class?
• And much more…
About ACS Webinars™
ACS Webinars™ is a free, weekly online event serving to connect ACS members and scientific professionals with subject matter experts and global thought leaders in chemical sciences, management, and business. The ACS Webinars are divided into several series that address topics of interest to the chemical and scientific community; these series include career development, professional growth, small & medium business, green chemistry, and executive view. Each webinar is 60 minutes in length, comprising a short presentation followed by Q&A with the speaker. The live webinars are held on Thursdays (and on some Tuesdays on career topics) from 2-3pm ET. Recordings of the webinars are available online and upcoming events are posted at http://acswebinars.org/.
|Topic:||drug development, drug, drug prototype||Audience:||pharmacist, students, chemists, general public, professors, research scientists|